{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:05:58Z","timestamp":1790431558133,"version":"4.1.0"},"reference-count":35,"publisher":"Impact Journals, LLC","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,4,13]]},"DOI":"10.18632\/oncotarget.24680","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T13:50:43Z","timestamp":1523627443000},"page":"19584-19596","source":"Crossref","is-referenced-by-count":9,"title":["Anti-cachectic effect of <i>Antrodia cinnamomea<\/i> extract in lung tumor-bearing mice under chemotherapy"],"prefix":"10.18632","volume":"9","author":[{"given":"Meng-Chuan","family":"Chen","sequence":"first","affiliation":[{"name":"School of Dentistry, Graduated Institute of Dental Science, National Defense Medical Center, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Lin","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan"},{"name":"School of Medicine, Tzu Chi University, Hualien, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tz-Chong","family":"Chou","sequence":"additional","affiliation":[{"name":"Cancer Research Center, Buddhist Tzu Chi General Hospital, Hualien, Taiwan"},{"name":"Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan"},{"name":"Department of Biotechnology, Asia University, Taichung, Taiwan"},{"name":"China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,4,13]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Ottery","year":"2011","journal-title":"Lancet Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ctrv.2013.11.007","article-title":"Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score","volume":"40","author":"McMillan","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.critrevonc.2013.07.015","article-title":"Clinical evaluation and optimal management of cancer cachexia","volume":"88","author":"Gasc\u00f3n","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MCO.0b013e3283455e21","article-title":"Cancer cachexia therapy: a key weapon in the fight against cancer","volume":"14","author":"Dalton","year":"2011","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"5","doi-asserted-by":"publisher","first-page":"601434","DOI":"10.1155\/2011\/601434","article-title":"Cancer cachexia: mechanisms and clinical implications","volume":"2011","author":"Reynolds","year":"2011","journal-title":"Gastroenterol Res Pract"},{"key":"6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jbspin.2007.04.019","article-title":"Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy","volume":"75","author":"Orazi","year":"2008","journal-title":"Joint Bone Spine"},{"key":"7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1096\/fj.03-0610com","article-title":"Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression","volume":"18","author":"Goldberg","year":"2004","journal-title":"FASEB J"},{"key":"8","doi-asserted-by":"publisher","first-page":"E495","DOI":"10.1152\/ajpendo.00389.2016","article-title":"Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiq uitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome","volume":"312","author":"Kim","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/10408363.2011.586171","article-title":"Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks","volume":"48","author":"Jagoe","year":"2011","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.tem.2016.03.002","article-title":"Cytokine signaling in skeletal muscle wasting","volume":"27","author":"Song","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"11","first-page":"665","article-title":"Chemotherapy: managing side effects and safe handling","volume":"50","author":"MacDonald","year":"2009","journal-title":"Can Vet J"},{"key":"12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.2001.19.4.1229","article-title":"Gemcitabine and cisplatin for advanced, metastatic bladder cancer","volume":"19","author":"Hayden","year":"2001","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.taap.2010.11.003","article-title":"Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems","volume":"250","author":"Aleo","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"14","doi-asserted-by":"publisher","first-page":"43442","DOI":"10.18632\/oncotarget.9779","article-title":"Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1\/2 and p38 MAPKs","volume":"7","author":"Bonetto","year":"2016","journal-title":"Oncotarget"},{"key":"15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jecm.2010.08.003","article-title":"Anticancer effects of taiwan of fugus camphoratus extracts, isolated compounds and its combinational use","volume":"2","author":"Sheu","year":"2010","journal-title":"J Exp Clin Med"},{"key":"16","doi-asserted-by":"publisher","first-page":"212641","DOI":"10.1093\/ecam\/nep108","article-title":"Review of pharmacological effects of antrodia camphorata and its bioactive compounds","volume":"2011","author":"Tzeng","year":"2011","journal-title":"Evid Based Complement Alternat Med"},{"key":"17","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.bbamcr.2011.06.002","article-title":"FoxO transcription factors; Regulation by AKT and 14-3-3 proteins","volume":"1813","author":"Ramakrishnan","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"18","doi-asserted-by":"publisher","first-page":"168407","DOI":"10.1155\/2014\/168407","article-title":"Inflammation based regulation of cancer cachexia","volume":"2014","author":"Guttridge","year":"2014","journal-title":"BioMed Res Int"},{"key":"19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"key":"20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Guttridge","year":"2012","journal-title":"Cell Metab"},{"key":"21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","article-title":"The role of myostatin in muscle wasting: an overview","volume":"2","author":"Springer","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"22","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.2527\/jas.2016-0532","article-title":"INVITED REVIEW: inhibitors of myostatin as methods of en hancing muscle growth and development","volume":"94","author":"Lee","year":"2016","journal-title":"J Anim Sci"},{"key":"23","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1245\/s10434-011-1720-5","article-title":"Changes in myostatin signaling in non-weight-losing cancer patients","volume":"19","author":"Muscaritoli","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1365-2362.2008.01970.x","article-title":"Muscle myostatin signalling is enhanced in experimental cancer cachexia","volume":"38","author":"Rossi Fanelli","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","article-title":"Role of interleukin-6 in cachexia: therapeutic implications","volume":"8","author":"Carson","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","article-title":"TNF-\u03b1 and cancer cachexia: molecular insights and clinical implications","volume":"170","author":"Patel","year":"2017","journal-title":"Life Sci"},{"key":"27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/cncr.11178","article-title":"Elevation of cytokine levels in cachectic patients with prostate carcinoma","volume":"97","author":"Corey","year":"2003","journal-title":"Cancer"},{"key":"28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.phanu.2013.07.002","article-title":"Molecular targets of cancer cachexia: opportunities for pharmanutritional approaches","volume":"2","author":"McFarlane","year":"2014","journal-title":"PharmaNutrition"},{"key":"29","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/bjp.2008.153","article-title":"Regulation of muscle mass by growth hormone and IGF-I","volume":"154","author":"Velloso","year":"2008","journal-title":"Br J Pharmacol"},{"key":"30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1097-2765(04)00211-4","article-title":"The IGF-1\/PI3K\/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO trans cription factors","volume":"14","author":"Glass","year":"2004","journal-title":"Mol Cell"},{"key":"31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2009.05.002","article-title":"Cytotoxic triterpenes from Antrodia camphorata and their mode of action in HT-29 human colon cancer cells","volume":"285","author":"Tzeng","year":"2009","journal-title":"Cancer Lett"},{"key":"32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jtcme.2014.11.026","article-title":"an active triterpenoid from the fruiting bodies of basswood cultivated Antrodia cinnamomea, induces mitochondria and endoplasmic reticulum stress-mediated apoptosis in human hepatoma cells","volume":"6","author":"Antcin","year":"2015","journal-title":"J Tradit Complement Med"},{"key":"33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jpba.2015.04.010","article-title":"Metabolites identification and multi-component pharmacokinetics of ergostane and lanostane triterpenoids in the anticancer mushroom Antrodia cinnamomea","volume":"111","author":"Ye","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"34","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/nprot.2009.95","article-title":"Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase","volume":"4","author":"Jacks","year":"2009","journal-title":"Nat Protoc"},{"key":"35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00280-008-0715-9","article-title":"Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution","volume":"63","author":"Souza","year":"2008","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24680","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:26:18Z","timestamp":1589041578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.24680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,13]]},"references-count":35,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2018,4,13]]}},"alternative-id":["24680","29731967"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.24680","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,13]]}}}